By Elric Langton | 30 March 2022
Poolbeg Pharma (AIM: POLB), a clinical-stage infectious disease pharmaceutical company with a unique capital-light clinical model, announces trading in the Companyโs Ordinary Shares of the nominal value of ยฃ0.02 each will commence today on the OTCQB Venture Market in the United States with the ticker: POLBF.
Over-the-countโฆ